0001086377-01-500004.txt : 20011107
0001086377-01-500004.hdr.sgml : 20011107
ACCESSION NUMBER: 0001086377-01-500004
CONFORMED SUBMISSION TYPE: SC 13G
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20011102
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCESS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000318306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 830221517
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-33655
FILM NUMBER: 1774035
BUSINESS ADDRESS:
STREET 1: 2600 N STEMMONS FRWY
STREET 2: STE 176
CITY: DALLAS
STATE: TX
ZIP: 75207
BUSINESS PHONE: 2149055100
MAIL ADDRESS:
STREET 1: 2600 N STEMMONS FRWY
STREET 2: STE 210
CITY: DALLAS
STATE: TX
ZIP: 75207
FORMER COMPANY:
FORMER CONFORMED NAME: CHEMEX CORP/WY
DATE OF NAME CHANGE: 19831102
FORMER COMPANY:
FORMER CONFORMED NAME: CHEMEX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19920703
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: GRAY KERRY P
CENTRAL INDEX KEY: 0001086377
STANDARD INDUSTRIAL CLASSIFICATION: []
FILING VALUES:
FORM TYPE: SC 13G
BUSINESS ADDRESS:
STREET 1: C/O ACCESS PHARMACEUTICALS INC
STREET 2: 2600 STEMMONS FRWY #176
CITY: DALLAS
STATE: TX
ZIP: 75207-2107
BUSINESS PHONE: 2149055100
MAIL ADDRESS:
STREET 1: C/O ACCESS PHARMACEUTICALS INC
STREET 2: 2600 STEMMONS FRWY #176
CITY: DALLAS
STATE: TX
ZIP: 75207-2107
SC 13G
1
r13g-003.txt
KERRY GRAY SCHEDULE 13G
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Act of 1934
Access Pharmaceuticals, Inc.
----------------------------
(Name of Issuer)
Common Stock, $.01 par value
----------------------------
(Title or Class of Securities)
00431M209
---------
(CUSIP Number)
September 13, 2001
-------------------------------------------------------
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule 13G is filed:
[ ] Rule 13d-1 (b)
[ X ] Rule 13d-1 (c)
[ ] Rule 13d-1 (d)
(Page 1 of 5 Pages)
CUSIP No. 00431M209 13G Page 2 of 5 Pages
1 NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS.
OF ABOVE PERSONS (ENTITIES ONLY) Kerry P. Gray
2 CHECK THE APPROPRIATE BOX IF
A MEMBER OF A GROUP (a) [ ]
(b) [X] Not Applicable
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION Australian
NUMBER OF 5 SOLE VOTING POWER 760,088 (including
SHARES 585,548 options)
BENEFICIALLY
OWNED BY 6 SHARED VOTING POWER -0-
EACH
REPORTING 7 SOLE DISPOSITIVE POWER 760,088 (including
PERSON 585,548 options)
WITH
8 SHARED DISPOSITIVE POWER -0-
9 AGGREGATE AMOUNT BENEFICIALLY
OWNED BY EACH REPORTING PERSON 760,088
10 CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ] Not Applicable
11 PERCENT OF CLASS REPRESENTED
AMOUNT IN ROW (9) 5.7%
12 TYPE OF REPORTING PERSON IN
CUSIP No. 00431M209 13G Page 3 of 5 Pages
Item 1(a). Name of Issurer:
The name of the issuer is Access Pharmaceuticals, Inc. (the "Company").
Item 1(b). Address of Issuer's Principal Executive Offices:
The Company's principal executive office is located at 2600 Stemmons Freeway,
Suite 176, Dallas, Texas 75207.
Item 2(a). Name of Person Filing:
The name of the person filing this Schedule 13G is Kerry P. Gray.
Item 2(b). Address of Principal Business Office or, if none, Residence
The business address of Mr. Gray is c/o Access Pharmaceuticals, Inc.,
2600 Stemmons Freeway, Suite 176, Dallas, TX 75207.
Item 2(c). Citizenship
Mr. Gray is a citizen of Australia and a Permanent Resident of the
United States.
Item 2(d). Title of Class of Securities
The title of the class of equity securities to which this statement relates
is the common stock, $.01 par value per share (the "Common Stock"), of Access
Pharmaceuticals, Inc., a Delaware corporation.
Item 2(e). CUSIP Number
00431M209
Item 3. If this statement is filed pursuant to Rules 13d-1 (b) or 13d-2 (b)
or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the Act,
(b) [ ] Bank as defined in section 3 (a) (6) of the Act,
(c) [ ] Insurance company as defined in section 3 (a) (19) of the Act,
(d) [ ] Investment company registered under section 8 of the Investment
Company Act of 1940,
CUSIP No. 00431M209 13D Page 4 of 5 Pages
(e) [ ] An investment advisor in accordance with Rule 13d-1 (b) (1) (ii) (E),
(f) [ ] An employee benefit plan or endowment fund in accordance with
Rule 13d-1 (b) (1) (ii) (F),
(g) [ ] A parent holding company or control person in accordance with
Rule 13d-1 (b) (1) (ii) (G),
(h) [ ] A savings association as defined in section 3(b) of the Federal
Deposit Insurance Act,
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c) (14) of the Investment
Company Act of 1940,
(j) [ ] Group, in accordance with Rule 13d-1 (b) (1) (ii) (J).
If this statement is filed pursuant to 13d-1 (c), check this box: [X]
Item 4. Ownership
(a) Amount beneficially owned: 760,088, which includes 585,548 options
that are vested or vest within 60 days
(b) Percent of class: 5.7%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 760,088, which includes
585,458 options that are vested or vest within 60 days
(ii) Shared power to vote or to direct the vote: -0-
(iii) Sole power to dispose or to direct the disposition of: 760,088,
which includes 585,458 options that are vested or vest within 60 days
(iv) Shared power to dispose or to direct the disposition of: -0-
Item 5. Ownership of Five percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
CUSIP No. 00431M209 13D Page 5 of 5 Pages
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Note applicable.
Item 9. Notice of Dissolution of Group
Note applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, correct
and complete.
Dated: November 1, 2001 /s/ Kerry P. Gray
------------------------
Kerry P. Gray